spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

6th Annual Cancer Vaccines Conference

SMI - 6th annual Cancer Vaccines Conference

27-28 September 2017
Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.

SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.

Aimed at an audience of senior scientists and oncology specialists involved in targeted vaccines and drug research, Cancer Vaccines 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of cancer immunotherapy. The 6th annual show will capture expert insight by honing in on new pathways with novel vaccines and immunotherapies, drug formulations, personalised treatment, immune check-point inhibitors, plus more.

Join us this September for strategic direction on vaccine commercialisation and arm yourself with the key requirements and tools for successful vaccine development through informed guidance delivered by a top panel of speakers.

Featured Speakers:

• Steve Doberstein, Senior Vice President and Chief Scientific Officer, Nektar
• Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology, MSD
• Fatema Legrand, Senior Clinical Scientist, Genentech
• David Giljohann, CEO, Exicure
• Steve Doberstein, Senior Vice President and Chief Scientific Officer, Nektar
• Agnete Fredriksen, Chief Scientific Officer, Vaccibody
• Mads Hald Andersen, Professor and Vice-Director, Centre for Cancer Immune Therapy, Copenhagen University Hospital; Founder, IO Biotech
• Rose-Ann Padua, Research Director, INSERM
• Zahra Jawad, Group Leader in Discovery Technology, Agenus

Exclusive highlights in 2017:

• Exploring personalising cancer vaccines, characterising and applying the outside in approach in cancer vaccine development
• Maximising the therapeutic potential of cancer vaccines in combination with immune checkpoint inhibitors
• In depth case study examples of peptide, DNA, neoantigen and MHC based vaccine development
• Assessing the use of preclinical data for cancer vaccines

Cancer Vaccines 2017 is sponsored by Northwest Biotherapeutics
phone +44 (0) 207 827 6012
email kwilliams@smi-online.co.uk
web bit.ly/2rAmHA3
email Copthorne Tara Hotel, London
 
Print this page
Send to a friend
   
spacer
Industry Events

ISPPP_2017

19-21 July 2017, Philadelphia, PA, USA

Mark your calendar to attend the premier meeting on state-of-the-art separation, analysis, and characterization methods, much of which is based on HPLC/UHPLC/Mass Spectrometry.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>


News and Press Releases

Merck to Provide Provantageฎ End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound


More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement